ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Eisai, Boston University collaborate

by Ryan Cross
February 5, 2018 | APPEARED IN VOLUME 96, ISSUE 6

Japanese drug company Eisai will expand its Alzheimer’s disease research through a collaboration between Boston University School of Medicine and the drug firm’s Andover innovative Medicines (AiM) Institute. The partnership is focused on the relationship between genetic variants related to Alzheimer’s and microglia, immune cells found in the brain. AiM Institute’s immuno-dementia research is part of a growing trend of searching for immune system- and inflammation-related targets to treat Alzheimer’s.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment